An analysis of UK Biobank datasets by PrecisionLife has found 13 ‘druggable’ targets
News
NICE backs use of Roche’s Gazyvaro with bendustamine
The treatment could benefit 500 people with follicular lymphoma
Janssen’s CAR-T shows 100% response rate in multiple myeloma
Longer-term follow-up data from CARTITUDE-1 study show an overall response rate of 100% while 86% experienced a complete response
Fast track for Moderna’s novel coronavirus vaccine
The move could help accelerate the development and review of the mRNA vaccine candidate
Oxford Biomedica bags MHRA nod for two manufacturing suites
The move will provide access to the Oxford COVID-19 Vaccine Consortium for production of vaccine should trials prove successful
NICE final guidance backs Pfizer’s Lorviqua
The drug meets NICE’s criteria to be considered a life-extending treatment
Over 50s COVID-19 trial launches across UK
PRINCIPLE is looking at whether existing drugs can be repurposed for older patients in the community who show signs of the disease
New partnership to sequence human genomes in fight against coronavirus
Thousands of patients severely ill with coronavirus are to have their genetic code studied to help uncover whether genetics play a role in susceptibility to the virus.
NHS England confirms four new ICSs
Around half of England’s population is now served by an ICS
Sanofi’s Sarclisa cuts death risk in mutiple myeloma
The Phase III IKEMA trial hit its primary endpoint
NIHR, UKRI call for new COVID-19 research proposals
The research funded will help inform policy decisions during the novel coronavirus pandemic
Lilly’s Retevmo wins US nod for specific lung, thyroid cancers
The selective RET kinase inhibitor was cleared under the regulator’s accelerated approval process
Cell and Gene Therapy Catapult links with Japan’s CiRA Foundation
The groups will explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicine products
Researchers assessing use of tick molecule for COVID-19
Evasins could prevent the progression of Acute Respiratory Distress Syndrome by acting as a ‘fire extinguisher’ to put out cytokine storms, researchers note
US nod for Lynparza in HRD-positive advanced ovarian cancer
Lynparza has been cleared for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
